OncoMatch/Clinical Trials/NCT07028086
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Is NCT07028086 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies VAM_GROUP for acute myeloid leukemia.
Treatment: VAM_GROUP — The mitoxantrone liposomal enhances the tissue permeability of mitoxantrone by incorporating liposomal groups compared to the conventional mitoxantrone formulation, while also reducing the concentration of free mitoxantrone, thereby minimizing drug side effects-particularly cardiotoxicity. Building upon this, the investigators aim to investigate the efficacy and safety of the liposomal mitoxantrone hydrochloride injection in patients with secondary AML, AML with extramedullary involvement, or myeloid sarcoma, in order to explore alternative therapeutic strategies for these populations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
serum creatinine ≤1.5x ULN
Liver function
ALT and AST ≤2.5x ULN (≤5x ULN for patients with liver involvement); total bilirubin ≤1.5x ULN
Cardiac function
Normal cardiac function, with LVEF ≥50%
Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%; ALT and AST ≤2.5 times the upper limit of normal (ULN) (≤5 times ULN for patients with liver involvement); total bilirubin ≤1.5 times ULN; serum creatinine ≤1.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify